Additional Professor, Indian Institute of Public Health-Delhi, Public Health Foundation of India, Gurgaon, Haryana, India.
Director, Indian Institute of Public Health-Delhi, Public Health Foundation of India, Gurgaon, Haryana, India.
Indian J Public Health. 2020 Jan-Mar;64(1):75-78. doi: 10.4103/ijph.IJPH_433_18.
The objective of this research was to generate the evidence on the private sector's contribution to overall immunization coverage for selected pediatric vaccines in India. Using IMS Health's (now IQVIA) vaccine sales audit data and innovative methodological approach we estimated private-sector vaccine share in the total immunization coverage across selected pediatric vaccines in India. Our estimates suggest that private sector remains an important contributor to immunization services in India not only for Universal Immunization Program vaccines (Bacillus Calmette-Guérin [19.23%], HiB pentavalent [11.09%], hepatitis B [5.75%], oral poliovirus vaccine [5.48%], Diphtheria-Pertussis-Tetanus [2.66%], and measles [2.17%]) but also for newer vaccines (hepatitis A [4.2%], rotavirus [3.4%], typhoid [3.3%], and pneumococcal conjugate vaccine [2.5%]). As the private sector continues to remain an important access point for immunization services in the country, avenues for potential synergy between public and private sectors should be explored to improve the coverage and quality of immunization services.
本研究旨在提供有关私营部门对印度选定儿科疫苗总体免疫覆盖率贡献的证据。我们使用 IMS Health（现为 IQVIA）的疫苗销售审计数据和创新的方法学方法，估算了私营部门在印度选定儿科疫苗总免疫覆盖率中的疫苗份额。我们的估计表明，私营部门不仅是印度免疫服务的重要贡献者，不仅为全民免疫计划疫苗（卡介苗 [19.23%]、乙型流感嗜血杆菌五联疫苗 [11.09%]、乙型肝炎疫苗 [5.75%]、口服脊髓灰质炎疫苗 [5.48%]、白喉-百日咳-破伤风疫苗 [2.66%] 和麻疹疫苗 [2.17%]），而且为新型疫苗（甲型肝炎疫苗 [4.2%]、轮状病毒疫苗 [3.4%]、伤寒疫苗 [3.3%] 和肺炎球菌结合疫苗 [2.5%]）。由于私营部门在该国继续成为免疫服务的重要准入点，应探索公私部门之间潜在协同作用的途径，以提高免疫服务的覆盖范围和质量。
